AVC

Quick links to important sections

AVC

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of AVC

The drug AVC is a prescription-only medicine formulated as a vaginal cream that acts as an antimicrobial agent to help manage localized infections. Its core identity is defined by its sole active component, Sulfanilamide, a synthetic compound which positions it within the historical Sulfonamide class of antibacterial medications.


AVC Quick Facts

Property Description
Active Ingredient Sulfanilamide
Form Vaginal Cream (Topical Preparation)
Pharmacological Class Antimicrobial Agent (Sulfonamide)
Origin Synthetic
General Purpose To halt bacterial growth and aid infection resolution

What Type of Medicine is AVC? (Identity and Classification)

AVC is primarily classified as an anti-infective agent belonging to the Sulfonamide group. These agents are distinguished from naturally occurring antibiotics because they are synthetic (man-made) compounds. Sulfonamides possess the ability to exert antimicrobial action. AVC is designed exclusively for topical use, meaning it is applied directly to the site of concern to concentrate its effect locally, rather than being absorbed into the bloodstream for systemic action. This focus on local delivery, often targeting conditions like non-specific vaginitis, is a key differentiating factor of the AVC formulation compared to oral Sulfonamides.


AVC's Composition and Form: Understanding Sulfanilamide Cream

The active ingredient in this medication is Sulfanilamide (the International Nonproprietary Name or INN). This single, primary compound is uniformly dispersed within a specialized cream base, which forms the semi-solid vaginal cream dosage form. As a single-ingredient product, all of its therapeutic benefits are derived exclusively from the local concentration of the Sulfanilamide, allowing for targeted delivery to the affected tissue surface. The cream formulation is designed to provide sustained contact and local coverage necessary for treating surface-level bacterial presence.


What is the General Purpose of This Antimicrobial Agent?

The general purpose of AVC is to control the population of susceptible bacteria associated with localized vaginal infections. It achieves this through a bacteriostatic action, a mechanism that works by interfering with the essential metabolic processes of the bacteria, specifically blocking the synthesis of folic acid necessary for the microbes to grow and multiply. In this process, Sulfanilamide interferes with the bacterial utilization of para-aminobenzoic acid (PABA) necessary for cell wall synthesis. By effectively halting the reproductive cycle of the targeted microorganisms, AVC supports the body's natural processes in resolving the underlying infection and related local discomfort.

Regulatory References

  1. cream formulation is clinically recognized
  2. MedlinePlus
  3. bacteriostatic
  4. folic acid

What side effects are possible with AVC?

Possible Side Effects and Safety Information

The safety profile for AVC (Sulfanilamide vaginal cream) is structured by the possibility of its active ingredient, Sulfanilamide, being absorbed systemically from the vaginal mucosa. This means the official labeling includes precautions for the serious, rare adverse reactions associated with the entire Sulfonamide drug class, alongside local effects.


Adverse Reaction Scope

The most commonly noted adverse reactions are local sensitivity responses, which may include a burning sensation or increased discomfort at the application site. These local effects are classified in regulatory texts as occasionally reported.

System-Organ Class Serious Adverse Reactions (Rare, Systemic Risk)
Blood and Lymphatic Aplastic anemia, Agranulocytosis, other Blood Dyscrasias
Skin and Immune System Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN)
Hepatobiliary Disorders Fulminant Hepatic Necrosis

Population-Specific and Use Constraints

Specific safety considerations are officially documented for certain groups. The medication is cautioned during the third trimester of pregnancy due to the drug's placental transfer. Its use is generally avoided in nursing mothers due to the risk of kernicterus in the infant. Furthermore, the cream formulation is noted to weaken rubber products, such as diaphragms and latex condoms, potentially leading to product failure. Contraindication applies to individuals with known hypersensitivity to any Sulfonamide.

Overdose and Emergency Response

AVC Overdose and when to seek help

The official overdose profile for AVC (Sulfanilamide Vaginal Cream) is built around the potential for systemic exposure and the resulting application of the usual precautions for oral sulfonamides. Regulatory documents state there have been no reports of accidental overdosage with AVC established in official records, and the minimum human lethal dose has not been established.

Documented Manifestations and Actions

Feature Official Regulatory Statement
Toxicity Manifestation Treatment must be discontinued immediately if skin rash or evidence of systemic toxicity occurs, due to absorption from the vaginal mucosa.
Life-Threatening Risks Potential fatal outcomes associated with the sulfonamide class include blood dyscrasias (such as agranulocytosis and aplastic anemia), severe hypersensitivity reactions, and hepatic necrosis.
Urgent Medical Help Immediate medical attention and contact with a Poison Control Center are required when evidence of systemic toxicity or signs of serious blood disorders (e.g., fever, purpura, or jaundice) manifest.
Management Note The regulatory label notes that it is not known if AVC is dialyzable, and no specific antidote is available.

The drug should also be avoided in nursing mothers as absorbed sulfonamides may cause kernicterus in the newborn, a population-specific risk noted in the label.

Therapeutic Uses of AVC

What AVC Treats: Main Uses and Benefits

The primary role of AVC (Sulfanilamide vaginal cream) is to provide localized anti-infective management for specific gynecological conditions and provides supportive symptomatic assistance.


Treatment of Vulvovaginal Candidiasis (Yeast Infections)

AVC is considered relevant in conditions characterized by an active fungal infection, specifically Vulvovaginal Candidiasis (VVC) caused by Candida albicans. The use of this medication is indicated in contexts where therapeutic support is needed for this specific condition. The key indications are generally applied in addressing the infectious episode and associated symptoms, including vaginal pruritus (itching), burning, and irritation. It is applied in situations where symptoms are driven by the presence of this susceptible pathogen, and supports the patient during difficult episodes by easing distress related to the infectious episode.


Relief from Local Inflammatory Symptoms

The medication may assist with symptom clusters that create noticeable interference with daily stability, focusing on symptoms related to inflammatory or irritative states. It is utilized when these symptoms become pronounced, and is used across domains where short-term symptomatic assistance is appropriate. It is commonly used to help with symptoms that create noticeable physiological strain, which can become more disruptive during flare-ups. AVC may provide support that helps ease the overall symptom load during the symptomatic phase, helping maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Symptomatic Relief Domains
AVC may be part of symptomatic management for vaginal pruritus and burning sensations, which are symptoms related to inflammatory or irritative states.

Eligibility and Restrictions for Use

Who can and cannot use AVC?

Eligibility for AVC (Sulfanilamide vaginal cream) is determined by regulatory bodies based on the potential for systemic absorption of the sulfonamide ingredient.


Contraindicated Populations

AVC is contraindicated and must not be used by specific groups as outlined in official labeling:

  • Hypersensitivity: Patients with known allergy to Sulfanilamide or to any medicine in the sulfonamide class.
  • Pregnancy: Women in the third trimester (after the seventh month) of pregnancy due to the risk of neonatal complications.
  • Lactation: Nursing mothers are advised against use, with regulators stating that the decision must be to discontinue nursing or discontinue the drug.
  • Blood Disorders: Patients with a history of severe blood disorders (blood dyscrasias).

Age and Condition Restrictions

Population Group Regulatory Status
Pediatric Patients (Under 18) Safety and effectiveness have not been established.
Infants (Under 2 months) Contraindicated.
Renal/Hepatic Impairment Use with caution is advised due to systemic absorption and the role of the liver and kidneys in metabolism/excretion.

The drug's use is generally established only for adult women (18 years of age and older).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns between AVC (Sulfanilamide topical) and other medicinal products, based strictly on regulatory sources.

Interaction-Related Restrictions

Certain combinations are subject to formal restrictions due to the documented potential for adverse outcomes or reduced efficacy. Co-administration with Mecamylamine is prohibited because Sulfanilamide may enhance its toxic effects. Co-administration with Progesterone is restricted due to the potential for the anti-infective agent to diminish the therapeutic effect of the progestational activity.

Category of Interacting Substance Official Interaction Outcome
Mecamylamine Co-administration prohibited (Enhanced toxic effects)
Progesterone Co-administration restricted (Diminished therapeutic effect)

Pharmacodynamic and Exposure Interactions

Regulatory information identifies interactions requiring therapeutic monitoring or noting altered drug concentrations. Co-administration with Ajmaline requires monitoring due to an increased risk for cholestasis, which is an officially documented adverse outcome enhancement. The therapeutic efficacy of Sulfanilamide may be reduced by co-administration with Ester-type Local Anesthetics, such as Procaine. Furthermore, Sulfanilamide may decrease the excretion rate of Benzylpenicillin, potentially resulting in a higher systemic exposure of Benzylpenicillin. Conversely, Bromhexine may increase the excretion rate of Sulfanilamide, which can lead to lower serum levels of the active ingredient.

Mechanism of Action

The Pharmacodynamic Mechanism of AVC

The action of AVC's ingredient, Sulfanilamide, is solely through an antimetabolite mechanism that selectively interferes with the growth and replication of susceptible bacteria.

This mechanism begins with competitive inhibition of the bacterial enzyme dihydropteroate synthase (DHPS). Sulfanilamide acts as a structural analog of para-aminobenzoic acid (PABA), binding to the DHPS enzyme and blocking the initiation of the necessary metabolic sequence.

This blockade abruptly interrupts the folic acid synthesis pathway, preventing the formation of tetrahydrofolic acid (THF), a critical cofactor. Since bacteria must synthesize their own THF for building DNA, RNA, and protein components, this mechanism is mechanistically selective because human cells obtain folic acid pre-formed.

By depleting THF, the drug starves the bacteria of necessary building blocks, which produces a bacteriostatic effect. This physiological arrest prevents further microbial proliferation. The mechanism, being bacteriostatic, requires host immune function to complete the elimination of the non-replicating microbial population.

Dosage and Administration Information

How AVC is Used: Official Administration Guidelines

AVC, a prescription-only medicine containing Sulfanilamide, is administered exclusively via the intravaginal route as a 15% cream. This method ensures the drug's action remains localized to the application site. The established protocol defines the precise dose and duration required to complete the prescribed therapeutic course.


Standard Dosing and Administration

The standard adult regimen involves the application of one applicatorful of the cream, which corresponds to approximately 6 g of the product, administered once or twice daily. The maximum number of applications should not exceed two per day. The full course of therapy requires consistent administration for a duration of 30 days. Treatment must be completed for the full specified duration, even if symptoms appear to subside.


Procedural Instructions and Constraints

The administration of AVC cream requires the use of the applicator provided by the manufacturer to ensure the correct dose is delivered to the vagina. Patients are instructed to continue treatment even if the menstrual period begins. A key procedural constraint is the prohibition of tampon use during therapy, as tampons may absorb the medication; sanitary pads should be used instead. The applicator must be thoroughly washed and dried after each use to maintain proper hygiene.


Population-Specific Use

For older adults, the standard dosing schedule is followed with no required adjustment. There are no specified dosage modifications for patients with renal or hepatic impairment, although the maximum daily dose should be observed. Safety and effectiveness have not been established for use in pediatric or adolescent patients.

Recent Clinical Evidence

Recent Clinical Evidence

This section summarizes published research and clinical studies that have evaluated the medication (AVC), focusing solely on study methodology and reported observations.


Overview of Clinical Trials

Primary Efficacy Studies

A number of randomized controlled trials (RCTs) and open-label extension studies have evaluated the medication in patients with joint inflammation across various populations. These studies primarily focused on objective measures, such as the number of swollen and tender joints, and patient-reported outcomes.

Studies assessed outcomes related to mobility using standardized assessment tools. Key outcomes monitored included quality of life scores and assessments of daily physical functioning. Long-term studies investigated the outcomes in relation to the severity and frequency of flare-ups over periods of up to five years.

Comparison with Existing Treatments

Comparative studies have been conducted against existing treatment methods, primarily focusing on established standard-of-care treatments. The primary endpoints in these head-to-head trials included changes in validated disease activity scores over a 12-week period.

Safety and Tolerability

Adverse Event Monitoring

Across all phases of clinical research, adverse events and tolerability were monitored in patients receiving the medication over extended periods. The most commonly reported events included injection site reactions and upper respiratory tract infections. No new safety signals were identified in the longer-term follow-up cohorts.

Studies in pediatric populations have evaluated tolerability and monitored for adverse events compared to adult trials.

Specialty Applications

Combination Treatments and Subgroups

Studies have examined the outcomes associated with combination treatment, where the medication was administered alongside another established therapeutic agent. Subgroup analysis has explored outcomes specifically in people with severe disease and in patients who had demonstrated an inadequate response to prior treatments.

Key Studies & References

  1. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
  2. Rheumatoid Arthritis Clinical Trials: Evaluating Efficacy, Mobility, and Long-term Outcomes

Frequently Asked Questions (FAQ)

Common questions about AVC (FAQ)

Q: Does AVC work for conditions other than its primary use?

A: According to the official prescribing information, AVC is approved only for the treatment of non-specific vaginitis caused by susceptible microorganisms. Its use for any other health conditions is not included in the regulatory documents.

Q: Can AVC be taken with common pain relievers like Tylenol or Advil?

A: The official prescribing information does not list specific interactions with common non-prescription pain relievers such as acetaminophen or ibuprofen. Information about potential drug interactions underscores the general principle that a healthcare professional should review all co-administered products.

Q: Is it safe to take AVC with vitamins or herbal supplements?

A: The regulatory documents do not specify known interactions between AVC and common vitamins or herbal supplements. Reporting all supplements and medications is a general practice when discussing a course of therapy.

Q: Does AVC have any known food interactions, like with grapefruit or dairy?

A: As a topical cream, the medication is applied locally. The official product information does not document any known interactions with food or drinks, such as grapefruit or dairy products.

Q: What is the official safety classification of AVC?

A: Official information indicates that AVC (Sulfanilamide topical) is classified by the FDA as Pregnancy Category C. Furthermore, the drug is not scheduled as a controlled substance under the Controlled Substances Act (CSA).

Q: What happens if I accidentally miss a dose of AVC?

A: If a dose is missed, regulatory instructions advise applying it as soon as it is remembered. If it is almost time for the next scheduled dose, regulatory instructions advise that only that dose is used, and a double amount is not recommended.

Q: Can AVC be taken on an empty stomach?

A: AVC is a cream designed for topical application directly to the vagina. As a result, the timing of meals or the contents of your stomach does not affect its use.

Q: Can AVC affect my ability to drive or operate machinery?

A: The official prescribing information does not include any specific warnings or precautions regarding the operation of machinery or driving while using AVC.

Q: Is AVC a habit-forming medicine?

A: AVC is not classified as a controlled substance, which is a category often associated with habit-forming potential. The regulatory label does not suggest that AVC has habit-forming properties.

Q: Does AVC interact with alcohol?

A: The official product information does not list any known interaction or restriction regarding the use of alcohol with AVC.

Q: Does the time of day matter when taking AVC?

A: The administration guidelines state that the cream should be used once or twice daily. The regulatory documents do not specify a required time of day.

Q: Are there any special tests or monitoring required while taking AVC?

A: No routine blood tests or special monitoring are typically required by the regulatory label for patients using the vaginal cream. Monitoring is only advised if interactions with other specific medications are present.

Q: How is AVC different from other medicines that treat the same condition?

A: AVC is distinguished by its composition as a synthetic sulfonamide drug. It is formulated exclusively as a topical vaginal cream to concentrate its antimicrobial effect locally at the site of infection.

Q: What health conditions is AVC approved to treat?

A: AVC is approved for the treatment of non-specific vaginitis (an infection) caused by certain types of susceptible microorganisms. This approval is based on official regulatory indications.

Q: How is the mechanism of action for AVC described in simple terms?

A: The drug works by preventing the bacteria from producing the essential nutrient, folic acid, that they need to grow and multiply. By blocking this step, it halts the bacterial reproductive cycle.

Q: Why is AVC sometimes prescribed when other drugs didn't work?

A: Clinical research has included studies specifically examining outcomes in patient subgroups who had previously demonstrated an inadequate response to prior treatments. The studies were designed to collect data from subgroups who had an inadequate response to prior treatments.

Q: What is the maximum amount of time AVC has been studied for continuous use?

A: Long-term clinical studies have monitored patient outcomes and tolerability for continuous use over periods of up to five years. Long-term clinical studies were conducted over periods of up to five years.

Q: Is AVC known to interact with birth control pills?

A: Regulatory documents indicate that AVC's active ingredient may diminish the therapeutic effect when co-administered with Progesterone. Progesterone is a hormone found in many birth control medications.

Q: How will I know if AVC is working for me?

A: AVC is designed to halt the growth of susceptible bacteria, which typically supports the body's natural process in resolving the underlying infection. Effectiveness is generally linked to the resolution of the localized infection and related discomfort.

Q: Why do some patients stop taking AVC?

A: Clinical trial monitoring indicates that the most commonly reported adverse reactions are local sensitivity responses. These include a burning sensation or increased discomfort at the application site, which may lead to discontinuation.

Q: What should I do if the appearance of my AVC pill changes (e.g., color, shape)?

A: AVC is a cream, not a pill. The official storage instructions state the product should be kept in its original, tightly closed container at controlled room temperature to prevent changes in appearance or stability.

Q: What are the main findings from the research evidence about AVC?

A: Clinical trials primarily focused on measuring changes in objective disease markers, such as the condition of the affected area, mobility, and patient-reported quality of life scores. The findings relate to these specific, validated metrics.

Q: Is the research for AVC considered high-quality or limited?

A: The clinical studies evaluating AVC include Randomized Controlled Trials (RCTs). Randomized Controlled Trials (RCTs) are a recognized study type for evaluating medication efficacy.

Q: Why is it important to tell my doctor about all the supplements I take when starting AVC?

A: The interaction profile of AVC highlights the potential for co-administered medications or products, including supplements, to lead to risks like diminished therapeutic effect or enhanced toxic effects. This potential risk profile indicates why comprehensive review of all products is necessary.

How should AVC be stored and disposed of?

How to Store and Dispose of AVC (Sulfanilamide Vaginal Cream)

The storage and disposal instructions for AVC are defined by official labeling to maintain product stability and ensure safety.

Storage Conditions

AVC vaginal cream must be stored at Controlled Room Temperature, specifically between 15 C to 30 C (59 F to 86 F). It is mandatory to keep the product in its original container, ensure it is tightly closed, and do not freeze the cream. Always store the medication out of the sight and reach of children.

Disposal Requirements

Unused or expired AVC should be disposed of by following established national guidelines. The product should not be flushed down a toilet or poured down a sink. If a drug take-back program is unavailable, mix the cream with an undesirable substance, like kitty litter or coffee grounds, and seal it in a bag before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of AVC found in:

A-Z Index: